Chronic Oral Administration of CI-994: A Phase I Study.

Autor: Prakash, Sucharu, Foster, Brenda, Meyer, Mark, Wozniak, Antoinette, Heilbrun, Lance, Flaherty, Lawrence, Zalupski, Mark, Radulovic, Louis, Valdivieso, Manuel, LoRusso, Patricia
Zdroj: Investigational New Drugs; Feb2001, Vol. 19 Issue 1, p1-11, 11p
Abstrakt: Objectives: CI-994 (N-acetyl dinaline, PD123654) is a novel oral agent active in a broad variety ofmurine and human tumor xenografts. While cytotoxic in theBrown Norway (BN) rat leukemia model, growth inhibition inother murine and human tumor xenografts is predominantlycytostatic. Its specific mechanism of action remains unknown.Following CI-994 administration, inhibition of both histonedeacetylation and cellular proliferation at the G1 to Stransition phase of the cell cycle are observed. This Phase 1study in patients with solid tumors was carried out todetermine a maximum tolerated daily oral dose (MTD) for CI-994administered on a chronic basis. Methods: Fifty-threepatients received CI-994 daily for treatment durations rangingfrom 2 to 10 weeks. Dosage escalation proceeded in 2 phases;an Acute Dosing Phase (n = 11) to define the MTD for CI-994administered over 2 weeks and a Chronic Dosing Phase (n = 29)to define the MTD for daily administration for 8 weeks. Uponcompletion of the Chronic Dosing Phase, a third cohort ofpatients (n = 13) received CI-994 at the recommended Phase 2dose and schedule with 2 additional single doses of drugadministered separated by a 1-week washout to assess theeffect of food on CI-994 pharmacokinetics. Results:Thrombocytopenia was dose limiting at the MTD of 8mg/m2/day for 8 weeks. Other toxicities includedfatigue and gastrointestinal effects such as nausea, vomiting,diarrhea, constipation and mucositis. Pharmacokinetic studiesrevealed that peak plasma levels and AUC's generally increasedwith dose and that food intake did not affect the rate orextent of drug absorption. One patient with heavilypre-treated adenocarcinoma of the lung achieved a PartialResponse (PR) lasting over 2 years and 3 additional patientsachieved Stable Disease (SD), 1 each with non-small cell lung,colorectal, and renal cancer. Conclusions: Therecommended Phase 2 starting dose is 8 mg/m2/dayfor 8 weeks repeated after a 2-week drug-freeinterval. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: